Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bakutrol A is a proprietary botanical cosmeceutical ingredient developed by Unigen, Inc., primarily for use in cosmetic and personal care products targeting acne and skin blemishes. It is a hydrolyzed extract derived from the seeds of *Psoralea corylifolia*, enriched to contain at least 60% bakuchiol. The ingredient functions as a multi-targeted agent with antimicrobial activity against acne-causing bacteria, inhibition of inflammatory enzymes including cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and 5-lipoxygenase (5-LOX), and potent antioxidant properties. Clinical studies have shown its effectiveness in reducing both inflammatory and non-inflammatory acne lesions and post-inflammatory hyperpigmentation without the irritation typically associated with synthetic treatments like benzoyl peroxide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bakutrol A.